Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Operating Expenses (2017 - 2025)

Cue Biopharma (CUE) has disclosed Operating Expenses for 9 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 78.11% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.0 million through Dec 2025, up 6.36% year-over-year, with the annual reading at $54.0 million for FY2025, 6.36% up from the prior year.
  • Operating Expenses hit $20.0 million in Q4 2025 for Cue Biopharma, up from $9.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $20.0 million in Q4 2025 to a low of $9.7 million in Q3 2025.
  • Historically, Operating Expenses has averaged $13.8 million across 5 years, with a median of $13.5 million in 2023.
  • Biggest five-year swings in Operating Expenses: fell 28.39% in 2024 and later soared 78.11% in 2025.
  • Year by year, Operating Expenses stood at $16.1 million in 2021, then fell by 7.0% to $15.0 million in 2022, then grew by 4.24% to $15.7 million in 2023, then dropped by 28.39% to $11.2 million in 2024, then skyrocketed by 78.11% to $20.0 million in 2025.
  • Business Quant data shows Operating Expenses for CUE at $20.0 million in Q4 2025, $9.7 million in Q3 2025, and $11.6 million in Q2 2025.